Deciphera Pharmaceuticals Quiet Period Ended This Week

Deciphera Pharmaceuticals will likely be pumped by the IPO underwriters soon now that the quiet period has ended.

Deciphera Pharmaceuticals’ quiet period ended on Tuesday, November 7, 2017. The brokerages that served as underwriters are working on research reports and will likely release those reports and analyst ratings on this company soon. In other words, the pump of this stock should start any week now. Please review this lesson on institutional traders and market makers.
Continue reading “Deciphera Pharmaceuticals Quiet Period Ended This Week”

Progenics Pharmaceuticals 142 Percent Price Target From Cantor Fitzgerald

Cantor Fitzgerald really went out high on Progenics Pharmaceuticals, or did they? Needham and Company also gave this stock its highest Strong Buy rating too.

Progenics Pharmaceuticals had its price target set to $15 by Cantor Fitzgerald. Cantor Fitzgerald has a Buy rating on the stock. Cantor Fitzgerald has struggled over the last year with its performance; however, Needham and Company hasn’t.
Continue reading “Progenics Pharmaceuticals 142 Percent Price Target From Cantor Fitzgerald”

Verastem Price Target Set 364 Percent Higher By Cantor Fitzgerald

Verastem stock had a price target set 364% higher than its current price by Cantor Fitzgerald. Cantor Fitzgerald has a buy rating on the stock.

Verastem is on track for duvelisib NDA in Q1 2018, to include accelerated approval request for follicular lymphoma. Duvelisib is a dual inhibitor of two enzymes called phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma. Both are associated with the growth and survival of malignant B cells and T cells.
Continue reading “Verastem Price Target Set 364 Percent Higher By Cantor Fitzgerald”

Sorrento Therapeutics Inc Bounce Off 61.8 Percent Retracement

Sorrento Therapeutics Inc has bounced off its 61.8 percent Fibonacci retracement level.
Continue reading “Sorrento Therapeutics Inc Bounce Off 61.8 Percent Retracement”

Verastem Inc Price Target Raised By Cantor Fitzgerald

Verastem Inc price target was raised to $17 by Cantor Fitzgerald last week. The new $17 price target represents 330% upside from the previous close of $3.95. Cantor has a Buy rating on the stock.

Cantor Fitzgerald is respected on Wall Street but they do not have the most accurate analysts IMO. Oppenheimer Holdings Inc is a more followed analyst than Cantor Fitzgerald. It’s no surprise then that I think it’s more significant that on October 12, 2017, Oppenheimer reiterated their Buy rating on Verastem Inc stock and set a price target of $6 which represents an upside of 52% from the previous close. The $6 price target seems more down-to-earth and achievable than Cantor’s stratospheric $17 price target.
Continue reading “Verastem Inc Price Target Raised By Cantor Fitzgerald”

Exelixis Gets FDA Priority Review for Cabomteyx

The FDA has granted priority review for Exelixis Cabomteyx. The sNDA seeks approval of Cabometyx for patients with previously untreated advanced renal cell carcinoma (RCC). The FDA determined the sNDA to be sufficiently complete. This means an FDA approval decision will be made by Feb. 15, 2018.
Continue reading “Exelixis Gets FDA Priority Review for Cabomteyx”

Exelixis Stock Oversold Continuation Pattern Setup

Exelixis stock looks like a good technical setup. The stock is oversold and looks to be trading inside a larger uptrending continuation pattern on the chart.
Continue reading “Exelixis Stock Oversold Continuation Pattern Setup”

Top 5 CAR T Stocks To Add To Your Watch List

CAR T stocks are the buzz right now. Even grocery store workers are talking about the FDA approval of the first CAR-T therapy from Novartis last week. Labiotech wrote about the Novartis CAR T approval here.

As swing traders we can’t chase any of these stocks. Back in July I wrote about going long both Cellectis and Novartis.

Back in February 2017 I linked to this YouTube video on how the National Cancer Institute cured leukemia that you may want to review to gain a fuller understanding of what this disruptive technology is about.

Had you bought Cellectis when I wrote about it back in July, you would be up more than 15% right now.

These stocks just can’t be chased higher right now.

My goal is that GuerillaStockTrading become the smartest stock trading website on the internet for amateur traders. Being smart means NEVER chasing a stock higher.

Most of you that watch the weekly Saturday show on YouTube already know that I made a New Year’s resolution to NEVER chase a stock higher in 2017. After making that resolution, my trading profits have improved by over 1000%.

You have to ask yourself, are you a predator or prey for some other predator? You want to be a predator. If you stalk and wait for a pullback to pounce, you’re a predator. If you chase a stock higher, you’re prey. Make sure to review this stock trading lesson on swing trading and the difference between being a predator or being prey.

CAR T Stocks

Be a smart trader. Instead of chasing, create a CAR T watch list and add these stocks to it:

CAR T Stocks Gilead

The next CART-T FDA approval will likely come from Gilead, which just announced the €10Bn acquisition of Kite Pharma that is currently waiting for an FDA decision on its CAR-T candidate KTE-C19.

GILD does not present an entry opportunity at the moment. Prices have been extended to the upside lately. For a good entry it is better to wait for a consolidation.

CAR T Stocks Novartis

Even though the FDA has approved Novartis’ CAR-T therapy Kymriah, officially blessing a new way to attack cancer, the stock has gone pretty much no where. That’s a cautionary yellow flag to traders who think that just because the FDA has approved a CAR-T therapy treatment that this translates into making money in CAR T stocks. Notice how the large players volume continues to downtrend and the Twiggs Money Flow is negative suggesting the stock is still under distribution. I think Novartis is a better setup for a long entry than Gilead. Prices have been consolidating lately and there is a support zone below the current price at $83.76, a stop order could be placed below this zone.

CAR T Stocks Cellectis

Cellectis is a death-trap stock. This is like the stock you tell your father-in-law to check out because it looks so good (wink, wink). Cellectis stock does NOT present a decent entry opportunity at the moment. Prices have been extended to the upside lately. For a good entry it is better to wait for a consolidation.

CAR T Stocks Juno Therapeutics

JUNO is a little better than CLLS but not by much. JUNO does not present a good swing long entry opportunity at the moment. Price movement has been a little bit too volatile to find a nice entry and exit point. It is probably a good idea to wait for more of a consolidation first.

CAR T Stocks Celyad

Large players have been selling CYAD into the upward move. We see reduced volatility while prices have been consolidating in the most recent period. There is a very little resistance above the current price. I don’t really like trading ADRs when I can find a similar opportunity in a non-ADR stock. The Twiggs Money Flow is weak and the falling large players volume means the stock is not a good setup right now unless both improve. I did this stock trading lesson on large players volume that you should review.

Make sure to leave your comments on CART T stocks and this exciting new medical technology below.

Novartis FDA Car T Approval – Most Exciting New Medicine Of Our Lifetimes

Big news: Novartis FDA Car T approval is likely coming soon after a Food and Drug Administration advisory panel unanimously recommended approval for Novartis’s leukemia drug tisagenlecleucel. The FDA usually follows its panels’ recommendations.

The big thing though will be price point. Car T is very expensive because it involves personalized treatment. If it’s too expensive, insurance companies won’t cover it.

Novartis FDA Car T

Novartis said that in patients with recurrent leukemia, 75% were still cancer free after CAR-T treatment.

Wells Fargo’s David Maris told clients that this ground-breaking approval is “the most exciting thing I’ve seen in my lifetime.”

CAR-T medicine is a new, personalized treatment which requires taking a patient’s own cells, removing them from the body, reengineering them for immunotherapy, and placing them back in the body.

The official Novartis FDA Car T approval is expected in October 2017.

Novartis Stock Chart

NVS has an ok setup pattern but I’m not really thrilled about it. I feel like we need more of a consolidation and a candle over candle reversal too so we know other buyers are stepping in at this level. There is a very little resistance above the current price. There is a support zone below the current price at 82.96, a stop order could be placed below this zone.